Annual EBITDA
-$545.07 M
+$797.00 K+0.15%
December 31, 2023
Summary
- As of February 7, 2025, SAGE annual EBITDA is -$545.07 million, with the most recent change of +$797.00 thousand (+0.15%) on December 31, 2023.
- During the last 3 years, SAGE annual EBITDA has fallen by -$1.17 billion (-186.99%).
- SAGE annual EBITDA is now -186.99% below its all-time high of $626.60 million, reached on December 31, 2020.
Performance
SAGE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$100.95 M
+$10.04 M+9.05%
September 30, 2024
Summary
- As of February 7, 2025, SAGE quarterly EBITDA is -$100.95 million, with the most recent change of +$10.04 million (+9.05%) on September 30, 2024.
- Over the past year, SAGE quarterly EBITDA has increased by +$10.04 million (+9.05%).
- SAGE quarterly EBITDA is now -110.36% below its all-time high of $974.50 million, reached on December 31, 2020.
Performance
SAGE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$371.15 M
+$76.97 M+17.18%
September 30, 2024
Summary
- As of February 7, 2025, SAGE TTM EBITDA is -$371.15 million, with the most recent change of +$76.97 million (+17.18%) on September 30, 2024.
- Over the past year, SAGE TTM EBITDA has increased by +$76.97 million (+17.18%).
- SAGE TTM EBITDA is now -155.69% below its all-time high of $666.40 million, reached on June 30, 2021.
Performance
SAGE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SAGE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.1% | +9.1% | +17.2% |
| 3 y3 years | -187.0% | +22.7% | -157.7% |
| 5 y5 years | -39.0% | +45.9% | +47.4% |
SAGE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -19.3% | +0.1% | -141.1% | +43.3% | at high | +43.5% |
| 5 y | 5-year | -187.0% | +22.8% | -110.4% | +43.3% | -155.7% | +47.4% |
| alltime | all time | -187.0% | +22.8% | -110.4% | +45.9% | -155.7% | +47.4% |
Sage Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$100.95 M(-9.0%) | -$371.15 M(-17.2%) |
| Jun 2024 | - | -$110.99 M(-5.4%) | -$448.13 M(-11.7%) |
| Mar 2024 | - | -$117.34 M(+180.2%) | -$507.26 M(-6.9%) |
| Dec 2023 | -$545.07 M(-0.1%) | -$41.88 M(-76.5%) | -$545.07 M(-17.0%) |
| Sep 2023 | - | -$177.92 M(+4.6%) | -$656.80 M(+5.9%) |
| Jun 2023 | - | -$170.13 M(+9.7%) | -$620.09 M(+7.3%) |
| Mar 2023 | - | -$155.15 M(+1.0%) | -$578.12 M(+5.9%) |
| Dec 2022 | -$545.87 M(+19.5%) | -$153.61 M(+8.8%) | -$545.90 M(+5.5%) |
| Sep 2022 | - | -$141.20 M(+10.2%) | -$517.44 M(+2.1%) |
| Jun 2022 | - | -$128.16 M(+4.3%) | -$506.76 M(+4.3%) |
| Mar 2022 | - | -$122.92 M(-1.8%) | -$485.73 M(+6.3%) |
| Dec 2021 | -$456.73 M(-172.9%) | -$125.15 M(-4.1%) | -$456.73 M(-171.0%) |
| Sep 2021 | - | -$130.52 M(+21.8%) | $642.92 M(-3.5%) |
| Jun 2021 | - | -$107.13 M(+14.1%) | $666.40 M(+0.4%) |
| Mar 2021 | - | -$93.92 M(-109.6%) | $663.63 M(+5.9%) |
| Dec 2020 | $626.60 M(-188.8%) | $974.50 M(-1010.4%) | $626.60 M(-220.1%) |
| Sep 2020 | - | -$107.04 M(-2.6%) | -$521.87 M(-13.2%) |
| Jun 2020 | - | -$109.90 M(-16.1%) | -$601.31 M(-9.9%) |
| Mar 2020 | - | -$130.96 M(-24.7%) | -$667.36 M(-5.5%) |
| Dec 2019 | -$705.84 M(+80.0%) | -$173.97 M(-6.7%) | -$705.84 M(+1.5%) |
| Sep 2019 | - | -$186.48 M(+6.0%) | -$695.73 M(+9.1%) |
| Jun 2019 | - | -$175.95 M(+3.8%) | -$637.71 M(+31.9%) |
| Mar 2019 | - | -$169.44 M(+3.4%) | -$483.66 M(+23.4%) |
| Dec 2018 | -$392.10 M | -$163.86 M(+27.6%) | -$392.10 M(+31.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$128.46 M(+486.5%) | -$298.55 M(+22.2%) |
| Jun 2018 | - | -$21.90 M(-71.9%) | -$244.32 M(-16.7%) |
| Mar 2018 | - | -$77.87 M(+10.7%) | -$293.15 M(+7.5%) |
| Dec 2017 | -$272.62 M(+70.5%) | -$70.31 M(-5.3%) | -$272.63 M(+5.4%) |
| Sep 2017 | - | -$74.24 M(+5.0%) | -$258.61 M(+16.3%) |
| Jun 2017 | - | -$70.72 M(+23.3%) | -$222.35 M(+19.2%) |
| Mar 2017 | - | -$57.35 M(+1.9%) | -$186.56 M(+16.7%) |
| Dec 2016 | -$159.88 M(+69.1%) | -$56.30 M(+48.2%) | -$159.88 M(+21.0%) |
| Sep 2016 | - | -$37.98 M(+8.7%) | -$132.16 M(+11.8%) |
| Jun 2016 | - | -$34.93 M(+13.9%) | -$118.24 M(+9.1%) |
| Mar 2016 | - | -$30.67 M(+7.3%) | -$108.33 M(+14.6%) |
| Dec 2015 | -$94.53 M(+180.0%) | -$28.58 M(+18.8%) | -$94.53 M(+20.7%) |
| Sep 2015 | - | -$24.05 M(-3.9%) | -$78.30 M(+22.9%) |
| Jun 2015 | - | -$25.03 M(+48.3%) | -$63.70 M(+42.0%) |
| Mar 2015 | - | -$16.88 M(+36.7%) | -$44.85 M(+32.9%) |
| Dec 2014 | -$33.76 M(+85.2%) | -$12.35 M(+30.5%) | -$33.76 M(+24.5%) |
| Sep 2014 | - | -$9.46 M(+53.1%) | -$27.11 M(+22.3%) |
| Jun 2014 | - | -$6.18 M(+6.9%) | -$22.17 M(+7.4%) |
| Mar 2014 | - | -$5.78 M(+1.4%) | -$20.63 M(+13.2%) |
| Dec 2013 | -$18.23 M(+90.2%) | -$5.70 M(+26.5%) | -$18.23 M(+45.5%) |
| Sep 2013 | - | -$4.51 M(-2.9%) | -$12.53 M(+56.2%) |
| Jun 2013 | - | -$4.64 M(+37.4%) | -$8.02 M(+137.4%) |
| Mar 2013 | - | -$3.38 M | -$3.38 M |
| Dec 2012 | -$9.59 M | - | - |
FAQ
- What is Sage Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Sage Therapeutics?
- What is Sage Therapeutics annual EBITDA year-on-year change?
- What is Sage Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sage Therapeutics?
- What is Sage Therapeutics quarterly EBITDA year-on-year change?
- What is Sage Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Sage Therapeutics?
- What is Sage Therapeutics TTM EBITDA year-on-year change?
What is Sage Therapeutics annual EBITDA?
The current annual EBITDA of SAGE is -$545.07 M
What is the all time high annual EBITDA for Sage Therapeutics?
Sage Therapeutics all-time high annual EBITDA is $626.60 M
What is Sage Therapeutics annual EBITDA year-on-year change?
Over the past year, SAGE annual EBITDA has changed by +$797.00 K (+0.15%)
What is Sage Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SAGE is -$100.95 M
What is the all time high quarterly EBITDA for Sage Therapeutics?
Sage Therapeutics all-time high quarterly EBITDA is $974.50 M
What is Sage Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SAGE quarterly EBITDA has changed by +$10.04 M (+9.05%)
What is Sage Therapeutics TTM EBITDA?
The current TTM EBITDA of SAGE is -$371.15 M
What is the all time high TTM EBITDA for Sage Therapeutics?
Sage Therapeutics all-time high TTM EBITDA is $666.40 M
What is Sage Therapeutics TTM EBITDA year-on-year change?
Over the past year, SAGE TTM EBITDA has changed by +$76.97 M (+17.18%)